Race Oncology at the heart of cancer care | News Direct

Race Oncology at the heart of cancer care

Race Oncology Ltd
News release by Race Oncology Ltd

facebook icon linkedin icon twitter icon pinterest icon email icon Melbourne, Victoria | August 09, 2023 03:00 PM Eastern Daylight Time

Race Oncology Ltd (ASX:RAC) CEO and managing director Damian Clarke-Bruce speaks with Proactive soon after launching a new corporate strategy focused on maximising bisantrene’s anti-cancer and cardio-protective potential.

The company’s lead clinical focus will be on investigating anti-cancer, plus cardio-protective and FTO (fat mass and obesity-associated protein) properties in metastatic breast cancer, using the peripherally administered bisantrene formulation, RC220 with a view to improving therapeutic outcomes and heart health for patients with cancer.

Clarke-Bruce said: “Race’s revised development program has been designed in such a way that our new bisantrene formulation can fit straight into a global pharmaceutical partner's pipeline.

“Through our rigorous clinical development plan, Race will investigate bisantrene RC220 in both metastatic breast cancer and continue our clinical experience in AML, while investigating and expanding our knowledge of its mechanism of action.

“We have a clear regulatory pathway and a program that is supported by international key opinion leaders, for a drug candidate which has already been shown to improve patients’ lives.”



Contact Details


Proactive Investors


Gregg Castano


+1 203-762-5649



project media


Race Oncology LtdbiotechAsxproactiveAustraliaproactiveInvestors